Tom Powles: Belzutifan attractive pretreated clear cell RCC
Tom Powles, Professor at the University of London, shared a post on X:
“Belzutifan attractive pretreated clear cell RCC, especially in patients with chronic VEFG tox where sequencing more TKIs gives diminishing returns.
Switching MOA here attractive with high efficacy and low tox vs everolimus. The Asian subset ESMO Asia24 is consistent with the ITT population.”
More posts featuring Tom Powles.
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.
His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023